Literature DB >> 11841899

Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis.

Magí Farré1, Anna Mas, Marta Torrens, Victor Moreno, Jordi Camí.   

Abstract

The efficacy of methadone maintenance in opioid addiction was assessed in terms of programme retention rate and reduction of illicit opioid use by means of a meta-analysis of randomised, controlled and double blind clinical trials. The results were compared with interventions using buprenorphine and levo-acetylmethadol (LAAM). Trials were identified from the PubMed database from 1966 to December 1999 using the major medical subject headings 'methadone' and 'randomised controlled trial'. Data for a total of 1944 opioid-dependent patients from 13 studies were analysed. Sixty-four percent of patients received methadone, administered either as fixed or adjusted doses. Thus, 890 patients received > or = 50 mg/day (high dose group) and 392 were given < 50 mg/day (low dose group). Of 662 controls, 131 received placebo, 350 buprenorphine (265 at doses > or = 8 mg/day and 85 at doses < 8 mg/day) and 181 LAAM. High doses of methadone were more effective than low doses in the reduction of illicit opioid use (odds ratio [OR] 1.72, 95% confidence interval [CI] 1.26--2.36). High doses of methadone were significantly more effective than low doses of buprenorphine (< 8 mg/day) for retention rates and illicit opioid use, but similar to high doses of buprenorphine (> or = 8 mg/day) for both parameters. Patients treated with LAAM had more risk of failure of retention than those receiving high doses of methadone (OR 1.92, 95% CI 1.32--2.78). It is proposed that in agonist-maintenance programmes, oral methadone at doses of 50 mg/day or higher is the drug of choice for opioid dependence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841899     DOI: 10.1016/s0376-8716(01)00171-5

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  47 in total

1.  Why we object to NAOMI. Heroin maintenance in Canada.

Authors:  Meldon Kahan; Anita Srivastava; Kay Shen
Journal:  Can Fam Physician       Date:  2006-06       Impact factor: 3.275

Review 2.  Misuse of and dependence on opioids: study of chronic pain patients.

Authors:  Meldon Kahan; Anita Srivastava; Lynn Wilson; Douglas Gourlay; Deana Midmer
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

3.  Treatment of opioid use disorder in an innovative community-based setting after multiple treatment attempts in a woman with untreated HIV.

Authors:  Pauline Voon; Ronald Joe; Christopher Fairgrieve; Keith Ahamad
Journal:  BMJ Case Rep       Date:  2016-07-11

4.  Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.

Authors:  Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2010-07-03

5.  Correlates of methadone client retention: a prospective cohort study in Guizhou province, China.

Authors:  Enwu Liu; Tao Liang; Limei Shen; Huan Zhong; Bing Wang; Zunyou Wu; Roger Detels
Journal:  Int J Drug Policy       Date:  2008-10-31

6.  Structural-level factors affecting implementation of the methadone maintenance therapy program in China.

Authors:  Chunqing Lin; Zunyou Wu; Keming Rou; Wenyuan Yin; Changhe Wang; Steven Shoptaw; Roger Detels
Journal:  J Subst Abuse Treat       Date:  2009-12-16

7.  Client retention in the British Columbia Methadone Program, 1996-1999.

Authors:  John F Anderson; Leanne D Warren
Journal:  Can J Public Health       Date:  2004 Mar-Apr

8.  Family Related Factors and Concurrent Heroin Use in Methadone Maintenance Treatment in China.

Authors:  Nan Feng; Chunqing Lin; Julie Hsieh; Keming Rou; Li Li
Journal:  Subst Use Misuse       Date:  2018-01-29       Impact factor: 2.164

9.  Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study.

Authors:  Mònica Astals; Laura Díaz; Antònia Domingo-Salvany; Rocío Martín-Santos; Antoni Bulbena; Marta Torrens
Journal:  Int J Environ Res Public Health       Date:  2009-11-12       Impact factor: 3.390

10.  Problem drug use the public health imperative: what some of the literature says.

Authors:  Gez Bevan
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.